Last reviewed · How we verify

Imfinzi (durvalumab)

AstraZeneca · FDA-approved active Monoclonal antibody Quality 62/100

Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells.

Imfinzi (durvalumab) is a programmed death ligand-1 blocker developed by AstraZeneca UK Ltd. It targets the PD-L1 protein to prevent cancer cells from evading the immune system. Imfinzi is approved to treat various types of cancer, including non-small cell lung cancer, small cell lung cancer, and liver cell carcinoma. The drug is patented and commercially available. Key safety considerations include immune-mediated adverse reactions and infusion-related reactions.

At a glance

Generic namedurvalumab
SponsorAstraZeneca
Drug classProgrammed Death Ligand-1 Blocker [EPC]
TargetProgrammed cell death 1 ligand 1
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approval2017
Annual revenue4900

Mechanism of action

Expression of programmed cell death ligand-1 (PD-L1) can be induced by inflammatory signals (e.g., IFN-gamma) and can be expressed on both tumor cells and tumor-associated immune cells in the tumor microenvironment. PD-L1 blocks T-cell function and activation through interaction with PD-1 and CD80 (B7.1). By binding to its receptors, PD-L1 reduces cytotoxic T-cell activity, proliferation, and cytokine production.Durvalumab is human immunoglobulin G1 kappa (IgG1) monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, without inducing antibody dependent cell-mediated cytotoxicity (ADCC).PD-L1 blockade with durvalumab led to increased T-cell activation in vitro and decreased tumor size in co-engrafted human tumor and immune cell xenograft mouse models.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: